INS and Alzheimer disease: Indeed, it is estimated that 46% of AD patient have impaired fasting glucose (Janson et al., 2004) and data suggest that a majority of AD patients have central insulin resistance (Steen et al., 2005; Talbot et al., 2012), suggesting that impaired insulin signaling might be a part of AD pathological process.